- Policy
- EUA of Lagevrio imminent…interest focused on its treatment
- by Lee, Jeong-Hwan Mar 23, 2022 05:51am
- Whether the US company Merck (MSD)’s oral COVID-19 treatment Lagevrio (molnupiravir) will settle in Korea as an alternative to Paxlovid (nirmatrelvir, ritonavir) is gaining attention. The company had applied for the emergency use authorization of molnupiravir to the Ministry of Food and Drug Safety in November last year but has not been
- Policy
- Rozlytrek & Vitrakvi are likely to be listed in April
- by Lee, Tak-Sun Mar 22, 2022 05:54am
- Bayer Korea's Vitrakvi and Roche Korea's Rozlytrek completed drug price negotiations and are likely to register their benefits in April. Both drugs are used to treat solid cancer in adults and children with confirmed NTRK gene fusion. If NTRK gene fusion is confirmed, it can be administered regardless of cancer. According to the industry o
- Policy
- Actemra is likely to be reimbursed for managing CRS
- by Kim, Jung-Ju Mar 21, 2022 05:55am
- Actemra (Tocilizumab 200mg), imported by JW Pharmaceutical and used to treat rheumatoid arthritis, is also expected to be paid for CRS management. The MOHW announced on the 18th some amendments to the "Details on the Application Criteria and Methods of Nursing Benefits" containing such contents. Actemra is a drug approved for adult rheumatoid
- Policy
- In/outpt Rx for Paxlovid are available in nursing hospitals
- by Lee, Jeong-Hwan Mar 21, 2022 05:55am
- Nursing hospitals will be able to prescribe outpatient & inpatient Rx for Paxlovid, a COVID-19 treatment. Both outpatient prescriptions that prepare and supply oral drugs at pharmacies in charge and inpatient prescriptions that receive oral drugs from hospitals dedicated to infectious diseases that supply treatments have become possible. The
- Policy
- Oral myeloid leukemia treatment Onureg to be soon approved
- by Lee, Hye-Kyung Mar 18, 2022 05:56am
- The domestic marketing authorization for BMS’s acute myeloid leukemia (AML) treatment, ‘Onureg tablet (azacytidine).’ Is imminent. The safety and efficacy review for the marketing authorization of Onureg, which had received FDA approval in 2020, is now complete in Korea. According to industry sources on the 16th, the Ministry of Foo
- Policy
- EUA approval of Actemra for severe COVID-19 over 2 yrs
- by Lee, Hye-Kyung Mar 17, 2022 05:58am
- Actemra can be used in severe COVID-19 patients over the age of 2. The MFDS (Director Kim Kang-rip) announced on the 15th that it approved EUA of Actemra imported by JW Pharmaceutical for severe COVID-19 patients aged two or older to prevent a shortage of treatments in advance. The seriousness referred to herein refers to hospitalized pati
- Policy
- Kymriah's price negotiation has rarely been concluded
- by Lee, Jeong-Hwan Mar 17, 2022 05:58am
- Two months after passing the Drug Benefit Evaluation Committee, negotiations on drug prices for acute lymphocytic leukemia and lymphoma CAR-T treatments have rarely been concluded. Leukemia patients are urging the NHIS and Novartis Korea to strengthen Kymriah's access to patients with rapid drug price negotiations. On the 15th, Korea Leuke
- Policy
- Expectations on Yoon Seok Yeol's government
- by Lee, Jeong-Hwan Mar 16, 2022 05:57am
- Expectations are growing for the Yoon Seok-yeol administration's policy to quickly register and expand benefits for ultra-high-priced medicines such as anticancer drugs and rare incurable disease drugs. This is the effect of Yoon Seok-yeol, the elected president of the People's Power, making a pledge to quickly register severe diseases and rare
- Policy
- Price of desvenlafaxine IMDs to be discounted up to 10%
- by Lee, Tak-Sun Mar 16, 2022 05:57am
- The price of the follow-on drugs of the anti-depressant ‘desvenlafaxine’ that had been listed at 90% of the price of its original by avoiding the original’s patent through salt alterations have fallen greatly after a year and a half due to the adjustment of the price cap that was conducted following an investigation into their actual tran
- Policy
- HPV vaccine, which costs 600,000 won, free of charge ?
- by Lee, Jeong-Hwan Mar 16, 2022 05:57am
- Human papilloma virus (HPV) vaccine, which costs about 200,000 won per inoculation and 600,000 won per inoculation, is expected to do well in the health insurance coverage of room 9. It is the gate that President-elect Yoon Seok-yeol promised to expand the insurance of Gadasil 9 as a life-friendly pledge. Looking at the 13th "59-second sho
